Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind study of BT001 for moderate-to-severe glabellar lines
CTR20251435Phase 2Active
- Sponsor
- Beijing Botewike Biotechnology
- Start
- Apr 2025
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of BT-001 in glabellar furrowing, sponsored by Beijing Botewike Biotechnology. Started Apr 2025; status: active.
02
Drugs
BT-001
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20251435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251435.